Cargando…

Progress in acute myeloid leukaemia: small molecular inhibitors with small benefits

The use of small molecule inhibitors in acute myeloid leukaemia (AML) has become ubiquitous with the US Food and Drug Administration approval of multiple agents between 2017 and 2018. Despite the promise, some of these indications are based on early efficacy data (phase I/II), and single-arm studies...

Descripción completa

Detalles Bibliográficos
Autor principal: Hilal, Talal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7105340/
https://www.ncbi.nlm.nih.gov/pubmed/32256698
http://dx.doi.org/10.3332/ecancer.2020.1015

Ejemplares similares